MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 130
- Market Cap
- $1.6B
About MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
SentiSense also tracks daily options readings for MoonLake Immunotherapeutics Class A Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
MoonLake Immunotherapeutics Class A Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.